| Regulatory status | PHASE 2 |
|---|---|
| Mechanism | Amylin analogue (once-weekly) |
| Developer | Eli Lilly |
| Form | Lyophilized powder · 20mg, 50mg |
| CAS | Investigational |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
Eloralintide is Eli Lilly’s once-weekly amylin analogue — a second-generation take on the amylin pathway that cagrilintide opened up. Phase 2 results were presented at EASD 2026. For labs tracking where the amylin class goes next, this is the compound to watch.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
Lilly's next-generation amylin candidate for weight management.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
